Study on the Mesothelin-specific Cytotoxicity Against Epithelial Ovarian Cancer with Full-length Mesothelin CDNA-transduced Dendritic Cells

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2015 Mar 18

PMID 25779534

Authors

Dong-Hui Wang

Xiao-hua Wu

Su-Min Qian

Hai-Rong Yao

Affiliations

Soon will be listed here.

Abstract

Epithelial ovarian cancer (EOC) has the highest mortality rate among the various types of gynecological cancers. As the current therapeutic approaches are not enough, the development of more effective treatments to improve the survival of patients with EOC is urgently needed. Mesothelin (MSLN) is a cell surface glycoprotein, which is overexpressed in ovarian cancer tissues. As an immunotherapeutic approach, in this study, we investigated whether the genetically modified dendritic cells (DCs) expressing MSLN could induce cytotoxic T lymphocytes (CTLs) to produce MSLN-specific cytotoxic activity against EOCs. Here, we report that DCs transfected with full-length coding sequence of MSLN could induce MSLN-specific CTLs responses against ovarian cancer lines SKOV3 and OVCAR3 in vitro. Additionally, we identified that the death rates of ovarian cancer cells, killed by MSLN-specific CTLs, were significantly higher than the normal CTLs. Furthermore, IFN-γ production by stimulated MSLN-specific CTLs was significantly higher than that of unstimulated CTLs. This study showed that induced CTLs by DCs with full-length MSLN cDNA have effective immune response against the ovarian cancer cells, indicating that MSLN-transfected DCs vaccine has a promising prospect for the treatment of EOC.

References

Palena C, Abrams S, Schlom J, Hodge J . Cancer vaccines: preclinical studies and novel strategies. Adv Cancer Res. 2006; 95:115-45. DOI: 10.1016/S0065-230X(06)95004-0. View

Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

Chang C, Wu T, Hung C . Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther. 2007; 14(16):1189-98. PMC: 3182456. DOI: 10.1038/sj.gt.3302974. View

Nishimura N, Nishioka Y, Shinohara T, Sone S . Enhanced efficiency by centrifugal manipulation of adenovirus-mediated interleukin 12 gene transduction into human monocyte-derived dendritic cells. Hum Gene Ther. 2001; 12(4):333-46. DOI: 10.1089/10430340150503966. View

Schlienger K, Chu C, Woo E, Rivers P, Toll A, Hudson B . TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res. 2003; 9(4):1517-27. View

Hassan R, Kreitman R, Pastan I, Willingham M . Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol. 2005; 13(3):243-7. DOI: 10.1097/01.pai.00000141545.36485.d6. View

Landis S, Murray T, Bolden S, Wingo P . Cancer statistics, 1999. CA Cancer J Clin. 1999; 49(1):8-31, 1. DOI: 10.3322/canjclin.49.1.8. View

Chang K, Pastan I . Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996; 93(1):136-40. PMC: 40193. DOI: 10.1073/pnas.93.1.136. View

Liao J, Disis M . Therapeutic vaccines for ovarian cancer. Gynecol Oncol. 2013; 130(3):667-73. DOI: 10.1016/j.ygyno.2013.06.023. View

10.

Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A . Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol. 2007; 31(2):277-83. View

11.

Feng Y, Xiao X, Zhu Z, Streaker E, Ho M, Pastan I . A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol Cancer Ther. 2009; 8(5):1113-8. PMC: 2891957. DOI: 10.1158/1535-7163.MCT-08-0945. View

12.

Chiang C, Maier D, Kandalaft L, Brennan A, Lanitis E, Ye Q . Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate. J Transl Med. 2011; 9:198. PMC: 3283529. DOI: 10.1186/1479-5876-9-198. View

13.

Hassan R, Bullock S, Premkumar A, Kreitman R, Kindler H, Willingham M . Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007; 13(17):5144-9. DOI: 10.1158/1078-0432.CCR-07-0869. View

14.

Ordonez N . Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003; 27(11):1418-28. DOI: 10.1097/00000478-200311000-00003. View

15.

Permuth-Wey J, Sellers T . Epidemiology of ovarian cancer. Methods Mol Biol. 2008; 472:413-37. DOI: 10.1007/978-1-60327-492-0_20. View

16.

Holschneider C, Berek J . Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000; 19(1):3-10. DOI: 10.1002/1098-2388(200007/08)19:1<3::aid-ssu2>3.0.co;2-s. View

17.

Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz R . Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001; 7(12):3862-8. View

18.

Gubbels J, Belisle J, Onda M, Rancourt C, Migneault M, Ho M . Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006; 5(1):50. PMC: 1635730. DOI: 10.1186/1476-4598-5-50. View

19.

Ryu B, Jones J, Blades N, Parmigiani G, Hollingsworth M, Hruban R . Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res. 2002; 62(3):819-26. View

20.

Ho M, Bera T, Willingham M, Onda M, Hassan R, Fitzgerald D . Mesothelin expression in human lung cancer. Clin Cancer Res. 2007; 13(5):1571-5. DOI: 10.1158/1078-0432.CCR-06-2161. View